Chaulagain et al., 2013 - Google Patents
New insights and modern treatment of AL amyloidosisChaulagain et al., 2013
View PDF- Document ID
- 9502903937593788255
- Author
- Chaulagain C
- Comenzo R
- Publication year
- Publication venue
- Current hematologic malignancy reports
External Links
Snippet
Systemic amyloidosis is a rare disease that is rarely cured. Systemic immunoglobulin light- chain amyloidosis (AL) is the most common type, usually the result of monoclonal light chains produced by a relatively indolent small plasma cell clone in the bone marrow. In AL …
- 208000005531 Immunoglobulin Light-chain Amyloidosis 0 title abstract description 44
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—G01N2333/4701
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
- G06Q50/10—Services
- G06Q50/22—Health care, e.g. hospitals; Social work
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
- G06F19/32—Medical data management, e.g. systems or protocols for archival or communication of medical images, computerised patient records or computerised general medical references
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chaulagain et al. | New insights and modern treatment of AL amyloidosis | |
Gertz et al. | Systemic amyloidosis recognition, prognosis, and therapy: a systematic review | |
Staron et al. | Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study | |
Gertz | Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018 | |
Wong et al. | Circulating tumor DNA analysis and functional imaging provide complementary approaches for comprehensive disease monitoring in metastatic melanoma | |
Comenzo et al. | Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis | |
Samimi et al. | Traceback: a proposed framework to increase identification and genetic counseling of BRCA1 and BRCA2 mutation carriers through family-based outreach | |
Mueller et al. | Clinical and histopathological features of patients with systemic sclerosis undergoing endomyocardial biopsy | |
Merlini et al. | Immunoglobulin light chain amyloidosis | |
Alvarado et al. | The value of repeat kidney biopsy in quiescent Argentinian lupus nephritis patients | |
Aaberg Jr et al. | Current clinical practice: differential management of uveal melanoma in the era of molecular tumor analyses | |
Lee et al. | Impact of completion lymph node dissection on patients with positive sentinel lymph node biopsy in melanoma | |
Godara et al. | Association between spinal stenosis and wild-type ATTR amyloidosis | |
Saba et al. | Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial | |
Hess et al. | Biomarker testing for patients with advanced/metastatic nonsquamous NSCLC in the United States of America, 2015 to 2021 | |
Patel et al. | Factors that impact turnaround time of surgical pathology specimens in an academic institution | |
JP6087888B2 (en) | Assay system for assessment of oncogenicity, tumor progression, and treatment efficiency | |
Rifkin et al. | Connect MM registry: the importance of establishing baseline disease characteristics | |
Muchtar et al. | Elevation of serum lactate dehydrogenase in AL amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation | |
Ferlini et al. | 204th ENMC international workshop on biomarkers in Duchenne muscular dystrophy 24–26 January 2014, Naarden, The Netherlands | |
Palladini et al. | Diagnosis and treatment of AL amyloidosis | |
van den Heuvel et al. | Facioscapulohumeral dystrophy transcriptome signatures correlate with different stages of disease and are marked by different MRI biomarkers | |
Gannon et al. | Results of implementation of amyloidosis screening for patients undergoing carpal tunnel release | |
Richards et al. | Abnormal uterine bleeding is associated with increased BMP7 expression in human endometrium | |
De Michieli et al. | Light-chain cardiac amyloidosis for the non-expert: pearls and pitfalls |